Antibody Ingredients TRIZ Cases

G237A Fc variant resists IdeS enzyme cleavage, enabling simultaneous administration without the standard four-day delay.

CD47 blockade converts protumor inflammation into systemic antitumor immunity, resolving limited abscopal effects.

Segmented single-domain antibody units assemble into multivalent constructs that block PD-1 interactions, resolving inadequate cancer treatment effectiveness.

Inhibin antibodies normalize tumor vasculature to reduce metastasis, avoiding toxicities from broad anti-angiogenic therapies.

Enzymatic glycosylation creates stable intermediates that resolve low site-control and instability in antibody-drug conjugate manufacturing.

Recombinant antibodies with optimized CDR sequences block AXL-mediated immune suppression, reducing tumor progression.

Convert multimeric antibody species into monomers using urea denaturants and reducing agents to reform correct disulfide bonds.

Combines IL-4/IL-13 pathway inhibitors with plasma cell ablating agents to eliminate allergen-specific IgE-producing cells.

Reducing glycosylation in chimeric 4D5 antibodies minimizes cardiotoxicity and immune responses while enhancing therapeutic efficacy.

mAb W6/800 targets distinct ERBB2 epitopes to overcome treatment resistance in ERBB2-low tumors, expanding therapeutic coverage beyond high-expression patients.

Addresses rapid relapse in small cell lung cancer by merging cytotoxic agents with immune-targeting antibodies to extend durable clinical responses.

Targeting MASP-2 blocks lectin pathway initiation, preventing tissue damage in aHUS and TTP while preserving classical immune defense.

Mutating IgG1 Fc residues at positions 238 and 297 reduces agonist signaling and toxicity without compromising CD40 binding affinity.

Novel BCMA antigen binding domain compositions utilize specific variable light and heavy domains to create therapeutic antibodies.

A multiparatopic antibody construct uses a common light chain to pair with multiple heavy chains for dual epitope targeting.

Administering guselkumab targets the IL-23p19 subunit to neutralize specific cytokine activity while preserving host defense mechanisms mediated by IL-12.

Arming cytotoxic immune cells with bispecific antibodies redirects tumor targeting to reduce systemic toxicity while enhancing anti-cancer efficacy.

Targeting iRhom2 reduces TNFα shedding, addressing clinical failures of direct ADAM17 inhibitors.

Merging DR5 agonist-induced apoptosis with PD-1 antagonist-mediated immune blockade overcomes tumor evasion mechanisms that limit single-agent efficacy.

A monoclonal antibody binds to the extracellular portion of human angiotensin converting enzyme 2.

An immunoconjugate links an anti-HER2 antibody to adjuvants via a polyethylene glycol linker for targeted delivery.

An antibody binds specifically to integrin alpha10 polypeptides on cancer cell surfaces.

Anti-NK1.1 antibody depletion of natural killer cells protects against adverse post-ischemic cardiac remodeling and reduces infarct size.

Specific antibody CDR regions target HER3 receptors to stop signal transduction, resolving ineffective current therapies.

Engineered antigen-binding protein constructs use pH-dependent dissociation to increase toxin liberation and cell killing in endolysosomes.

Incorporating an immunomodulating agent reduces neutrophil expansion and IL-6 levels, mitigating immune reactogenicity to allow higher tolerable doses.

A luminal domain LGAM tracer binds to cytotoxic T cells for detection via positron emission tomography.